These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27568021)

  • 1. Genomic profiling of breast cancer in African-American women using MammaPrint.
    Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
    Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
    Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
    Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
    Gevensleben H; Göhring UJ; Büttner R; Heukamp LC; Kunz G; Dimpfl T; Jackisch C; Ortmann O; Albert US; Bender R; De Snoo F; Krijgsman O; Glas AM; Ergönenc YH; Vogel C; Dykgers A; Langwieder C; Rees M; Anzeneder T
    Int J Mol Med; 2010 Dec; 26(6):837-43. PubMed ID: 21042777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
    Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
    Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
    Viale G; Slaets L; Bogaerts J; Rutgers E; Van't Veer L; Piccart-Gebhart MJ; de Snoo FA; Stork-Sloots L; Russo L; Dell'Orto P; van den Akker J; Glas A; Cardoso F;
    Ann Oncol; 2014 Apr; 25(4):816-823. PubMed ID: 24667714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
    Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.
    Zhang H; Katerji H; Turner BM; Audeh W; Hicks DG
    Mod Pathol; 2022 Aug; 35(8):1075-1082. PubMed ID: 35184150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
    Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
    Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
    Göker E; Hendriks MP; van Tilburg M; Barcaru A; Mittempergher L; van Egmond A; Kleijn M; Generali D;
    Eur J Cancer; 2022 May; 167():92-102. PubMed ID: 35421703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and clinical landscape of ER + /PR- breast cancer in China.
    Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
    BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
    Arciero CA; Yang J; Peng L; Ward KC; O'Regan R; Sahin AA; Li X
    Breast Cancer Res Treat; 2017 Dec; 166(3):743-755. PubMed ID: 28856481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.